IN THE SPOTLIGHT

Twenty Lung Cancer Advocacy Organizations and 23andMe Come Together to Launch Lung Cancer Genetics Study to Help Advance Research

Twenty Lung Cancer Advocacy Organizations and 23andMe Come Together to Launch Lung Cancer Genetics Study to Help Advance Research

FDA approves Roche’s Alecensa as the first adjuvant treatment for people with ALK-positive early-stage lung cancer

FDA approves Roche’s Alecensa as the first adjuvant treatment for people with ALK-positive early-stage lung cancer

Nuvalent To Present Updated Data For ROS1-Selective Inhibitor, Zidesamtinib, And ALK-Selective Inhibitor, NVL-655, At The ESMO Congress 2024

Nuvalent To Present Updated Data For ROS1-Selective Inhibitor, Zidesamtinib, And ALK-Selective Inhibitor, NVL-655, At The ESMO Congress 2024

Practice Updates in Lung Cancer Stem From Biomarker Testing and Up-Front Immunotherapy

Practice Updates in Lung Cancer Stem From Biomarker Testing and Up-Front Immunotherapy

Key Data Updates From ASCO May Advance the Treatment Landscapes of 3 Lung Cancer Subtypes

Key Data Updates From ASCO May Advance the Treatment Landscapes of 3 Lung Cancer Subtypes

Lung Cancer Expert at ASCO: From Fatal to 'Chronic Disease'

Lung Cancer Expert at ASCO: From Fatal to 'Chronic Disease'

Lung Cancer Was a Death Sentence. Now Drugs Are Saving Lives.

Lung Cancer Was a Death Sentence. Now Drugs Are Saving Lives.

Lung Cancer Was a Death Sentence. Now Drugs Are Saving Lives.

Lung Cancer Was a Death Sentence. Now Drugs Are Saving Lives.

Lorbrena Yields “Unprecedented” Progression-Free Survival for ALK-Positive Lung Cancer

Lorbrena Yields “Unprecedented” Progression-Free Survival for ALK-Positive Lung Cancer

'Outstanding' 5 Year Progression-Free Survival With Lorlatinib in ALK+ NSCLC

'Outstanding' 5 Year Progression-Free Survival With Lorlatinib in ALK+ NSCLC

ASCO 2024: New study details longest progression-free survival ever reported in advanced NSCLC

ASCO 2024: New study details longest progression-free survival ever reported in advanced NSCLC

NVL-655 Receives FDA Breakthrough Therapy Designation in ALK+ NSCLC

NVL-655 Receives FDA Breakthrough Therapy Designation in ALK+ NSCLC

Alectinib Lands FDA Approval for Adjuvant Therapy in NSCLC

Alectinib Lands FDA Approval for Adjuvant Therapy in NSCLC

FDA approves Alecensa for certain patients with ALK-positive lung cancer

FDA approves Alecensa for certain patients with ALK-positive lung cancer

FDA Approves Alectinib to Treat Patients With ALK-Positive NSCLC

FDA Approves Alectinib to Treat Patients With ALK-Positive NSCLC

Alectinib in Resected ALK-Positive Non-Small-Cell Lung Cancer

Alectinib in Resected ALK-Positive Non-Small-Cell Lung Cancer

Treating Women With Lung Cancer: Screening, Treatment, and Sexual and Reproductive Health

Treating Women With Lung Cancer: Screening, Treatment, and Sexual and Reproductive Health

Is Immunotherapy Beneficial in Patients with Oncogene-Addicted Non-Small Cell Lung Cancers? A Narrative Review

Is Immunotherapy Beneficial in Patients with Oncogene-Addicted Non-Small Cell Lung Cancers? A Narrative Review

Dr Mark Socinski on How Targeted Therapies Have Impacted Lung Cancer Outcomes

Dr Mark Socinski on How Targeted Therapies Have Impacted Lung Cancer Outcomes

Real-World Outcomes of Immunotherapy in Second- or Later-Line Non-Small Cell Lung Cancer with Actionable Genetic Alterations

Real-World Outcomes of Immunotherapy in Second- or Later-Line Non-Small Cell Lung Cancer with Actionable Genetic Alterations

ICYMI: Alecensa Exhibited Unprecedented Results for Patients with Early-Stage Lung Cancer

ICYMI: Alecensa Exhibited Unprecedented Results for Patients with Early-Stage Lung Cancer

Alectinib shows promise in early-stage ALK-positive non-small cell lung cancer

Alectinib shows promise in early-stage ALK-positive non-small cell lung cancer

Brigatinib Not Superior to Alectinib in ALK-Positive NSCLC

Brigatinib Not Superior to Alectinib in ALK-Positive NSCLC

Phase 3 Trial Results Show Adjuvant Alectinib Reduces Recurrence, Mortality in Early-Stage ALK-Positive NSCLC

Phase 3 Trial Results Show Adjuvant Alectinib Reduces Recurrence, Mortality in Early-Stage ALK-Positive NSCLC

Alectinib Meets DFS End Point in ALK+ Early-Stage NSCLC

Alectinib Meets DFS End Point in ALK+ Early-Stage NSCLC

Trial-first for Roche lung cancer ALK inhibitor

Trial-first for Roche lung cancer ALK inhibitor

Following in Tecentriq's footsteps, Alecensa gives Roche another win in early-stage lung cancer

Following in Tecentriq's footsteps, Alecensa gives Roche another win in early-stage lung cancer

Genentech's Alecensa shows promise in Phase III study for early-stage ALK-positive lung cancer

Genentech's Alecensa shows promise in Phase III study for early-stage ALK-positive lung cancer


Roche claims study success for targeted drug in early lung cancer


Roche claims study success for targeted drug in early lung cancer

A Look at NSCLC and Its Current and Emerging Therapies

A Look at NSCLC and Its Current and Emerging Therapies